Overview

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Status:
Completed
Trial end date:
2021-09-21
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics